Skip to main content
. Author manuscript; available in PMC: 2021 Jul 16.
Published in final edited form as: Cancer Prev Res (Phila). 2020 Aug 24;13(11):911–922. doi: 10.1158/1940-6207.CAPR-20-0200

Figure 1: The cirrhotic liver harbors many neoantigens and may respond to immunotherapy.

Figure 1:

Neoantigen burden was analyzed in (A) human cirrhosis samples and (B) human HCC samples. (C) Predicted neoantigen burden increases from human cirrhosis to HCC (Student’s t-test, two tailed, equal variance). All data are presented as mean ± SEM. ***p < 0.001.